State of the Art ReviewCancer

On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

+ See all authors and affiliations

Science Translational Medicine  25 Mar 2015:
Vol. 7, Issue 280, pp. 280sr1
DOI: 10.1126/scitranslmed.3010274

You are currently viewing the abstract.

View Full Text


The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level.

View Full Text

Related Content